We are live on ! Find out more
Pacer Advisors

Pacer Advisors Portfolio holdings

AUM $35.6B
1-Year Est. Return 18.19%
This Fund
S&P 500
This Quarter Est. Return
+6.91%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$1.43B
AUM Growth
+$297M
Cap. Flow
+$228M
Cap. Flow %
16%
Top 10 Hldgs %
15.34%
Holding
1,414
New
222
Increased
745
Reduced
184
Closed
249

Top Buys

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$11.4M
2
AAPL icon
Apple
AAPL
+$9.16M
3
MSFT icon
Microsoft
MSFT
+$6.62M
4
META icon
Meta Platforms (Facebook)
META
+$5.96M
5
AMZN icon
Amazon
AMZN
+$5.23M

Sector Composition

Rank Sector Weight
1 Technology 18.28%
2 Financials 14.25%
3 Healthcare 11.99%
4 Industrials 10.61%
5 Consumer Discretionary 9.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PGEN icon
1051
Precigen
PGEN
$1.93B
$31K ﹤0.01%
+2,650
New +$39.5K
XLRN
1052
DELISTED
Acceleron Pharma
XLRN
$31K ﹤0.01%
+725
New +$27.2K
FMI
1053
DELISTED
Foundation Medicine, Inc.
FMI
$31K ﹤0.01%
+450
New +$23.3K
SGMO
1054
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$30K ﹤0.01%
+1,850
New +$27.5K
EXPR
1055
DELISTED
Express, Inc.
EXPR
$30K ﹤0.01%
147
-81
-36% -$13.3K
FLXN
1056
DELISTED
Flexion Therapeutics, Inc.
FLXN
$30K ﹤0.01%
+1,200
New +$29.4K
SGYP
1057
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$30K ﹤0.01%
+13,382
New +$33.3K
TDAY
1058
USA Today Co
TDAY
$1.23B
$29K ﹤0.01%
1,715
-1,359
-44% -$22.1K
HRTX icon
1059
Heron Therapeutics
HRTX
$86.3M
$29K ﹤0.01%
+1,600
New +$26.1K
OXM icon
1060
Oxford Industries
OXM
$577M
$29K ﹤0.01%
385
-150
-28% -$10K
RYAM icon
1061
Rayonier Advanced Materials
RYAM
$565M
$29K ﹤0.01%
1,432
-927
-39% -$15.6K
TBI
1062
Trueblue
TBI
$234M
$29K ﹤0.01%
1,051
-1,067
-50% -$28.3K
TGTX icon
1063
TG Therapeutics
TGTX
$8.58B
$28K ﹤0.01%
+3,425
New +$29.9K
EFII
1064
DELISTED
Electronics for Imaging
EFII
$28K ﹤0.01%
938
-134
-13% -$4.49K
MEI icon
1065
Methode Electronics
MEI
$543M
$27K ﹤0.01%
664
-449
-40% -$20K
SPPI
1066
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$27K ﹤0.01%
+1,407
New +$25.5K
TVTY
1067
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$27K ﹤0.01%
+751
New +$28.5K
CSGS
1068
DELISTED
CSG Systems International
CSGS
$26K ﹤0.01%
+584
New +$25.2K
ENTA icon
1069
Enanta Pharmaceuticals
ENTA
$372M
$26K ﹤0.01%
+450
New +$22.5K
PTCT icon
1070
PTC Therapeutics
PTCT
$6.37B
$26K ﹤0.01%
+1,550
New +$26.2K
RGEN icon
1071
Repligen
RGEN
$7.44B
$26K ﹤0.01%
+725
New +$26.2K
DPLO
1072
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$26K ﹤0.01%
+1,272
New +$25K
BHE icon
1073
Benchmark Electronics
BHE
$2.91B
$25K ﹤0.01%
869
-1,123
-56% -$35K
CROX icon
1074
Crocs
CROX
$6.69B
$24K ﹤0.01%
+1,917
New +$20.5K
MNTA
1075
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$24K ﹤0.01%
+1,750
New +$23.7K

Similar funds

Pacer Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Pacer Advisors held 1,414 positions worth $1.43B, up 26% from $1.13B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Pacer Advisors deployed $228M of net new capital in Q4 2017, opening 222 new positions and adding to 745 existing holdings. Its largest new stake was Equinor: 118,925 shares worth $2.55M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Alphabet (Google) Class C, an estimated $3.14M trimmed.

  • Pacer Advisors's largest Q4 2017 buy was Equinor: 118,925 shares worth $2.55M.
  • Pacer Advisors added most to Alphabet (Google) Class A in Q4 2017, an estimated $11.4M increase.
  • Pacer Advisors's biggest Q4 2017 reduction was Alphabet (Google) Class C, cutting an estimated $3.14M.
  • Pacer Advisors fully exited Adient in Q4 2017, selling an estimated $1.67M.
  • Pacer Advisors's ten largest holdings make up 15% of its $1.43B portfolio in Q4 2017.
  • Pacer Advisors opened 222 new positions and closed 249 in Q4 2017.
  • Pacer Advisors's portfolio value rose 26% quarter-over-quarter to $1.43B.

Based on Pacer Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.